Taylor Morrison Home Corporation (NYSE:TMHC) (the “Company”) today announced that its Board of Directors has increased the amount available for repurchases under its stock repurchase program by up to $250 million of the Company’s Common Stock. Repurchases of the Company’s Common Stock under the program will occur from time to time in open market purchases, privately negotiated transactions or other transactions through December 31, 2022.
Immuron Announced Request for AU$5.4M (US$4M) Additional Funding from the U.S. Department of Defense for Travelan Considered to be Eligible for Award
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to advise that a new request for funding has been considered to be eligible for award by the US Department of Defense funding body ‘Medical Technology Enterprise Consortium' (MTEC).
